| Natural flavonoids targeting deregulated cell cycle progression in cancer cells. | |
| | |
MedLine Citation:
|
PMID: 16515531 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The prolonged duration requiring alteration of multi-genetic and epigenetic molecular events for cancer development provides a strong rationale for cancer prevention, which is developing as a potential strategy to arrest or reverse carcinogenic changes before the appearance of the malignant disease. Cell cycle progression is an important biological event having controlled regulation in normal cells, which almost universally becomes aberrant or deregulated in transformed and neoplastic cells. In this regard, targeting deregulated cell cycle progression and its modulation by various natural and synthetic agents are gaining widespread attention in recent years to control the unchecked growth and proliferation in cancer cells. In fact, a vast number of experimental studies convincingly show that many phytochemicals halt uncontrolled cell cycle progression in cancer cells. Among these phytochemicals, natural flavonoids have been identified as a one of the major classes of natural anticancer agents exerting antineoplastic activity via cell cycle arrest as a major mechanism in various types of cancer cells. This review is focused at the modulatory effects of natural flavonoids on cell cycle regulators including cyclin-dependent kinases and their inhibitors, cyclins, p53, retinoblastoma family of proteins, E2Fs, check-point kinases, ATM/ATR and survivin controlling G1/S and G2/M check-point transitions in cell cycle progression, and discusses how these molecular changes could contribute to the antineoplastic effects of natural flavonoids. |
| | |
Authors:
|
Rana Pratap Singh; Rajesh Agarwal |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Current drug targets Volume: 7 ISSN: 1389-4501 ISO Abbreviation: Curr Drug Targets Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2006-03-06 Completed Date: 2006-04-20 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 100960531 Medline TA: Curr Drug Targets Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 345-54 Citation Subset: IM |
Affiliation:
|
Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, 4200 East Ninth Street, Box C238, Denver, CO 80262, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents, Phytogenic / pharmacology*, therapeutic use Cell Cycle / drug effects* Cell Differentiation / drug effects Flavonoids / pharmacology* Gene Expression Regulation, Neoplastic / drug effects Humans Neoplasms / drug therapy*, genetics, pathology* |
| Grant Support | |
ID/Acronym/Agency:
|
R01 CA102514/CA/NCI NIH HHS; R01 CA64514/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Phytogenic; 0/Flavonoids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors.
Next Document: Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1).